To evaluate the efficacy of Lodhradi Yonivarti in Shwetapradara

Phase 4

Not yet recruiting

• Conditions: Diseases of the genitourinary system. Ayurveda Condition: YONIROGAH/YONI-VYAPADAH,

• Registration Number: CTRI/2025/05/086437
• Lead Sponsor: Dr Madhura Balu Kale

Brief Summary

Yonivarti is meant for Shodhana Karma.It is beneficial for treating conditions relatedto vaginal canal and uterus. It helps cleanse the vaginal canal by removing harmful doshas andsupports the restoration of balanced vaginal health.The high vascularity of vaginal wall and pelvictissue enables faster absoption of drugs than oral administration.The anatomical position of vaginaalso enhances the drug action in situ.Trial drug Lodhradi Yonivarti acts by its stambhaka,sravanashaka, tridoshashamaka, vranaropana and kapha shodhana properties.[8] In Modern medicine,various formulations are used for vulvovaginalinfection.Control drug ‘Clingen forte’ contains fixed combination of Clindamycin, Clotrimazole&Tinidzole ensures wide range of antimicrobial action with rapid and symptomatic relief in patientinfected by bacterial,fungal and protozoal origin. It gives significant relief from vaginal infection ofmixed origin.[9] Considering these properties of ‘Lodhradi Yonivarti’ and ‘Clingen forte (Vaginal suppository)’,these drugs are selected for study.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-03-05
• Study Start: 2025-05-14

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

• Married patients of age 18 to 45 years.
• 2. Patients having p/v white discharge (srava) with sthanik kandu ,srava gandha ,katishool or any one of these .
• 3. Patients ready to participate in study with proper written consent.
• 4. Patient irrespective of a) Religion b) Cast c) Socio economic status d) Occupation.

Exclusion Criteria

• 1. Pregnancy.
• 2. Patients with surgical intervention such as a Cervical polyp, uterine prolapse.
• 3. Patients suffering from HIV, STD, Hepatitis B.
• 4. Patients diagnosed with malignancies of genital tract.
• 5. Oral contraceptive pills users.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Srava pramana that is amount of discharge	7 days

Secondary Outcome Measures

Name	Time	Method
Srava gandha that is smell	sthanik kandu that is per vaginal itching

Trial Locations

Locations (1)

Seth RV Ayurvedic Hospital; 🇮🇳 Mumbai, MAHARASHTRA, India

Seth RV Ayurvedic Hospital

🇮🇳Mumbai, MAHARASHTRA, India

Dr Madhura Balu Kale

Principal investigator

8329625709

madhukale7276@gmail.com